nach oben

Current Hypertension Reports

Erschienen in:

01.05.2014 | Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)

Alterations in Cardiac Structure and Function in Hypertension

verfasst von: Mário Santos, Amil M. Shah

Erschienen in: Current Hypertension Reports | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Hypertension is a powerful risk factor for cardiovascular mortality and morbidity, including heart failure with both preserved and reduced ejection fraction. Hypertensive heart disease (HHD) defines the complex and diverse perturbations of cardiac structure and function occurring secondary to hypertension. Left ventricular hypertrophy (LVH) is one of the most recognized features of HHD and is an established risk factor for adverse cardiovascular (CV) outcomes in hypertension. Beyond LVH, LV geometry provides additional information regarding the cardiac response to hypertension. Imaging studies from larger cohorts of hypertensive patients reveal wide variability in the prevalence of LVH and LV geometric patterns, with the prevalence of concentric LVH similar to that of eccentric LVH. Hypertension is also associated with concomitant impairments in LV diastolic and systolic function. It remains uncertain why patients develop different patterns of LVH, although demographics and clinical comorbidities appear to influence that response.

Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.PubMed

Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, et al. Predictors of new-onset heart failure: Differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6:279–86.PubMedCentralPubMed

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2013 update: A report from the american heart association. Circulation. 2013;127:e6–245.PubMed

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMed

Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: A meta-analysis of randomised controlled studies. Heart. 2014;100:317–23.

Georgiopoulou VV, Kalogeropoulos AP, Raggi P, Butler J. Prevention, diagnosis, and treatment of hypertensive heart disease. Cardiol Clin. 2010;28:675–91.PubMed

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 esh/esc guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). Eur Heart J. 2013;34:2159–219.PubMed

Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (lvh) in systemic hypertension (sh)-possible therapeutic perspectives. J Am Soc Hypertens. 2011;5:449–55.PubMed

Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med. 1992;327:998–1008.PubMed

10.

Gosse P, Cremer A, Vircoulon M, Coulon P, Jan E, Papaioannou G, et al. Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. J Hypertens. 2012;30:2403–9.PubMed

11.

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322:1561–6.PubMed

12.

Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580–6.PubMed

13.

Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960;5:370–82.PubMed

14.

Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: Stimuli, patterns, and consequences. Hypertens Res. 1999;22:1–9.PubMed

15.

Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–52.PubMed

16.

Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550–8.PubMed

17.

Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56–64.PubMedCentralPubMed

18.

Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45–79.PubMed

20.••

Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327–34. A review of the major pathophysiologic mechanisms underlying hypertensive heart disease and an informative discussion of the diverse pathways that it can take in the progression to heart failure.PubMed

20.

Iwashima Y, Horio T, Kamide K, Tokudome T, Yoshihara F, Nakamura S, et al. Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension. Am J Hypertens. 2010;23:290–8.PubMed

21.

Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: Data from the pamela population. Pressioni arteriose monitorate e loro associazioni. Hypertension. 2002;39:744–9.PubMed

22.

Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: An updated review of echocardiographic studies. J Hum Hypertens. 2012;26:343–9.PubMed

23.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the american society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.PubMed

24.

Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. Lv mass assessed by echocardiography and cmr, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 2012;5:837–48.PubMedCentralPubMed

25.

Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K. The effect of left ventricular remodelling on soluble st2 in a cohort of hypertensive subjects. J Hum Hypertens. 2014. doi:10.1038/jhh.2013.130.

26.

Sinning C, Keller T, Zeller T, Ojeda F, Schluter M, Schnabel R, Lubos E, Bickel C, Lackner KJ, Diemert P, Munzel T, Blankenberg S, Wild PS. Association of high-sensitivity assayed troponin i with cardiovascular phenotypes in the general population: The population-based gutenberg health study. Clin Res Cardiol. 2014;103:211–22.

27.

Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, et al. Relation between soluble st2, growth differentiation factor-15, and high-sensitivity troponin i and incident atrial fibrillation. Am Heart J. 2014;167:109–115.e2.

28.

de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: The cardiovascular health study. Eur Heart J. 2008;29:741–7.PubMed

29.

Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: The assessment of prognostic risk observational survey. J Hypertens. 2002;20:1307–14.PubMed

30.

Andrikou E, Tsioufis C, Thomopoulos C, Andrikou I, Kasiakogias A, Leontsinis I, et al. Left ventricular mass index as a predictor of new-onset microalbuminuria in hypertensive subjects: A prospective study. Am J Hypertens. 2012;25:1195–201.PubMed

32.••

Frohlich ED, Gonzalez A, Diez J. Hypertensive left ventricular hypertrophy risk: Beyond adaptive cardiomyocytic hypertrophy. J Hypertens. 2011;29:17–26. A comprehensive review of the pathophysiological mechanisms underlying hypertensive heart disease.PubMed

32.

Eguchi K, Kario K, Hoshide S, Ishikawa J, Morinari M, Shimada K. Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients. Am J Hypertens. 2005;18:23–9.PubMed

33.

Conrady AO, Rudomanov OG, Zaharov DV, Krutikov AN, Vahrameeva NV, Yakovleva OI, et al. Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: The st. Petersburg study. Blood Press. 2004;13:101–9.PubMed

34.

Adebayo RA, Bamikole OJ, Balogun MO, Akintomide AO, Adeyeye VO, Bisiriyu LA, et al. Echocardiographic assessment of left ventricular geometric patterns in hypertensive patients in nigeria. Clin Med Insights Cardiol. 2013;7:161–7.PubMedCentralPubMed

35.

Devereux RB, de Simone G, Ganau A, Roman MJ. Left ventricular hypertrophy and geometric remodeling in hypertension: Stimuli, functional consequences and prognostic implications. J Hypertens Suppl. 1994;12:S117–27.PubMed

36.

Fox ER, Taylor J, Taylor H, Han H, Samdarshi T, Arnett D, et al. Left ventricular geometric patterns in the jackson cohort of the atherosclerotic risk in communities (aric) study: Clinical correlates and influences on systolic and diastolic dysfunction. Am Heart J. 2007;153:238–44.PubMed

37.

Akintunde A, Akinwusi O, Opadijo G. Left ventricular hypertrophy, geometric patterns and clinical correlates among treated hypertensive nigerians. Pan Afr Med J. 2010;4:8.PubMed

38.

Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health study). Am J Cardiol. 2001;87:1051–7.PubMed

39.

Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: The dallas heart study. Hypertension. 2005;46:124–9.PubMed

40.

Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, et al. Differences in left ventricular structure between black and white hypertensive adults: The hypertension genetic epidemiology network study. Hypertension. 2004;43:1182–8.PubMed

41.

Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72:310–3.PubMed

42.

Kuch B, Muscholl M, Luchner A, Doring A, Riegger GA, Schunkert H, et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens. 1998;12:685–91.PubMed

43.

Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, et al. Relations of serum aldosterone to cardiac structure: Gender-related differences in the framingham heart study. Hypertension. 2004;43:957–62.PubMed

44.

Saba MM, Ibrahim MM, Rizk HH. Gender and the relationship between resting heart rate and left ventricular geometry. J Hypertens. 2001;19:367–73.PubMed

45.

Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J. 1998;135:58–66.PubMed

46.

Teuscher A, Egger M, Herman JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch Intern Med. 1989;149:1942–5.PubMed

47.

Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: A systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327–38.PubMedCentralPubMed

48.

Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension genetic epidemiology network (hypergen) study. Circulation. 2001;103:102–7.PubMed

49.

Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the framingham heart study). Am J Cardiol. 1991;68:85–9.PubMed

50.

Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation. 2000;101:2271–6.PubMed

51.

Buono F, Crispo S, Pagano G, Rengo G, Petitto M, Grieco F, et al. Determinants of left ventricular hypertrophy in patients with recent diagnosis of essential hypertension. J Hypertens. 2014;32:166–73.PubMed

52.

Chrostowska M, Szyndler A, Hoffmann M, Narkiewicz K. Impact of obesity on cardiovascular health. Best Pract Res Clin Endocrinol Metab. 2013;27:147–56.PubMed

53.

de Simone G. Morbid obesity and left ventricular geometry. Hypertension. 2007;49:7–9.PubMed

55.••

Owan T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, et al. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the utah obesity study. J Am Coll Cardiol. 2011;57:732–9. This study provides empiric evidence of the reversibility of cardiac changes associated with obesity.PubMedCentralPubMed

55.

Luaces M, Cachofeiro V, Garcia-Munoz-Najar A, Medina M, Gonzalez N, Cancer E, et al. Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery. Rev Esp Cardiol (Engl). 2012;65:14–21.

56.

Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: A systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014;32:16–25.PubMed

57.

Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.PubMed

58.

Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85–97.PubMed

59.

Grabysa R, Wankowicz Z. Echocardiographic markers of left ventricular dysfunction among men with uncontrolled hypertension and stage 3 chronic kidney disease. Med Sci Monit. 2013;19:838–45.PubMedCentralPubMed

60.

Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334–41.PubMed

61.

Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol. 2010;5:805–13.PubMedCentralPubMed

62.

Hashimoto J, Westerhof BE, Westerhof N, Imai Y, O'Rourke MF. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment. J Hypertens. 2008;26:1017–24.PubMed

63.

Kobayashi S, Yano M, Kohno M, Obayashi M, Hisamatsu Y, Ryoke T, et al. Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. Circulation. 1996;94:3362–8.PubMed

64.

Lai S, Coppola B, Dimko M, Galani A, Innico G, Frassetti N, et al. Vitamin d deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease. Ren Fail. 2014;36:58–64.PubMed

65.

Martinez-Vea A, Marcas L, Bardaji A, Romeu M, Gutierrez C, Garcia C, et al. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clin Nephrol. 2012;77:171–81.PubMed

66.

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25:871–8.PubMed

67.

Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F, Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens. 2004;17:1035–9.PubMed

68.

Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004;43:731–8.PubMed

69.•

Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Left ventricular geometry and outcomes in patients with atrial fibrillation: The affirm trial. Int J Cardiol. 2014;170:303–8. This study demonstrates that even in a population at high-risk for cardiovascular events, hypertension-associated changes in cardiac structure provides independent prognostic information.PubMed

70.

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol. 1996;78:197–202.PubMed

71.

Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998;31:1635–40.PubMed

72.

Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the framingham heart study. J Am Coll Cardiol. 1995;25:879–84.PubMed

73.

Velagaleti RS, Gona P, Pencina MJ, Aragam J, Wang TJ, Levy D, et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. Am J Cardiol. 2014;113:117–22.PubMed

74.••

Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: With special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011;58:1733–40. A comprehensive review of the importance of considering geometric cardiac changes in a wide spectrum of cardiovascular diseases.PubMed

75.

Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: The dallas heart study. Circ Cardiovasc Imaging. 2010;3:164–71.PubMed

76.•

Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahlof B, Roman MJ, et al. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: The losartan intervention for endpoint reduction in hypertension study. J Hypertens. 2013;31:2060–8. Echocardiographic substudy of a clinical trial demonstrating that including left ventricle volume in the classification of cardiac geometry can improve the detection of systolic dysfunction in hypertensive patients.PubMed

77.

Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The strong heart study. Circulation. 2002;105:1928–33.PubMed

78.

Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.PubMed

79.

de Simone G, Kitzman DW, Chinali M, Oberman A, Hopkins PN, Rao DC, et al. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: The hypergen study. Eur Heart J. 2005;26:1039–45.PubMed

80.

ADVANCE Echocardiography Substudy Investigators, ADVANCE Collaborative Group.. Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: The advance echocardiography substudy. J Hypertens. 2011;29:721 1439–1447.

81.

Sharp AS, Tapp RJ, Thom SA, Francis DP, Hughes AD, Stanton AV, et al. Tissue doppler e/e' ratio is a powerful predictor of primary cardiac events in a hypertensive population: An ascot substudy. Eur Heart J. 2010;31:747–52.PubMed

82.

Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the life study). Losartan intervention for endpoint. Am J Cardiol. 2000;85:466–72.PubMed

83.

Pearson AC, Labovitz AJ, Mrosek D, Williams GA, Kennedy HL. Assessment of diastolic function in normal and hypertrophied hearts: Comparison of doppler echocardiography and m-mode echocardiography. Am Heart J. 1987;113:1417–25.PubMed

84.

Douglas PS, Berko B, Lesh M, Reichek N. Alterations in diastolic function in response to progressive left ventricular hypertrophy. J Am Coll Cardiol. 1989;13:461–7.PubMed

85.

Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. New insights into the relationship of left ventricular geometry and left ventricular mass with cardiac function: A population study of hypertensive subjects. Eur Heart J. 2010;31:588–94.PubMed

86.

Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial size: Physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47:2357–63.PubMed

87.

Tsioufis C, Stougiannos P, Taxiarchou E, Skiadas I, Chatzis D, Thomopoulos C, et al. The interplay between haemodynamic load, brain natriuretic peptide and left atrial size in the early stages of essential hypertension. J Hypertens. 2006;24:965–72.PubMed

88.

Cuspidi C, Rescaldani M, Sala C. Prevalence of echocardiographic left-atrial enlargement in hypertension: A systematic review of recent clinical studies. Am J Hypertens. 2013;26:456–64.PubMed

89.

Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, et al. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: The strong heart study (shs). Am Heart J. 2006;151:412–8.PubMed

90.

Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: Prevalence, determinants, and prognostic value. Hypertension. 2005;45:412–8.PubMed

91.

The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The solvd investigattors. N Engl J Med. 1992;327:685–691.

92.

Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995;26:195–202.PubMed

93.

de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996;93:259–65.PubMed

94.

Narayanan A, Aurigemma GP, Chinali M, Hill JC, Meyer TE, Tighe DA. Cardiac mechanics in mild hypertensive heart disease: A speckle-strain imaging study. Circ Cardiovasc Imaging. 2009;2:382–90.PubMed

95.

Kosmala W, Plaksej R, Strotmann JM, Weigel C, Herrmann S, Niemann M, et al. Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: An ultrasonic two-dimensional speckle tracking study. J Am Soc Echocardiogr. 2008;21:1309–17.PubMed

96.

Leggio M, Sgorbini L, Pugliese M, Mazza A, Bendini MG, Fera MS, et al. Systo-diastolic ventricular function in patients with hypertension: An echocardiographic tissue doppler imaging evaluation study. Int J Cardiovasc Imaging. 2007;23:177–84.PubMed

97.

Rosen BD, Edvardsen T, Lai S, Castillo E, Pan L, Jerosch-Herold M, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: The multi-ethnic study of atherosclerosis. Circulation. 2005;112:984–91.PubMed

98.

de Simone G, Kitzman DW, Palmieri V, Liu JE, Oberman A, Hopkins PN, et al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction: The hypergen study. Am J Hypertens. 2004;17:828–33.PubMed

100.•

Cuspidi C, Sala C, Muiesan ML, De Luca N, Schillaci G. Right ventricular hypertrophy in systemic hypertension: An updated review of clinical studies. J Hypertens. 2013;31:858–65. A recent review that calls attention to the impact of hypertension on the right ventricle.PubMed

100.

Cuspidi C, Negri F, Giudici V, Valerio C, Meani S, Sala C, et al. Prevalence and clinical correlates of right ventricular hypertrophy in essential hypertension. J Hypertens. 2009;27:854–60.PubMed

101.

Ivanovic BA, Tadic MV, Celic VP. To dip or not to dip? The unique relationship between different blood pressure patterns and cardiac function and structure. J Hum Hypertens. 2013;27:62–70.PubMed

102.

Lourenco AP, Roncon-Albuquerque Jr R, Bras-Silva C, Faria B, Wieland J, Henriques-Coelho T, et al. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291:H1587–94.PubMed

103.

Laks MM, Morady F. Norepinephrine–the myocardial hypertrophy hormone? Am Heart J. 1976;91:674–5.PubMed

104.

Tadic M, Cuspidi C, Suzic-Lazic J, Andric A, Stojcevski B, Ivanovic B, Hot S, Scepanovic R, Celic V. Is there a relationship between right-ventricular and right atrial mechanics and functional capacity in hypertensive patients? J Hypertens. 2014

106.••

Barron AJ, Hughes AD, Sharp A, Baksi AJ, Surendran P, Jabbour RJ, et al. Long-term antihypertensive treatment fails to improve e/e' despite regression of left ventricular mass: An anglo-scandinavian cardiac outcomes trial substudy. Hypertension. 2014;63:252–8. An echocardiographic substudy of a hypertension therapeutic trial demonstrating a divergent effect of antihypertensive treatment on left ventricle hypertrophy and diastolic function.PubMed

106.

Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084–91.PubMed

107.

Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, et al. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: The losartan intervention for endpoint reduction in hypertension (life) study. Am Heart J. 2002;144:1057–64.PubMed

108.

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet. 2007;369:2079–87.PubMed

109.

Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55:241–8.PubMed

110.

Almuntaser I, Mahmud A, Brown A, Murphy R, King G, Crean P, et al. Blood pressure control determines improvement in diastolic dysfunction in early hypertension. Am J Hypertens. 2009;22:1227–31.PubMed

111.

Diez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension. 2010;55:1–8.PubMed

112.

Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation. 2013;128:388–400.PubMed

Titel: Alterations in Cardiac Structure and Function in Hypertension
verfasst von: Mário Santos
Amil M. Shah
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 5/2014
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-014-0428-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension

Angiotensin-(1-12): A Chymase-Mediated Cellular Angiotensin II Substrate

Autonomic Nervous System Dysregulation in Pediatric Hypertension